FDA advisory panel backs easier pharmacy access to peptide therapies

An FDA advisory panel has voted to allow specialised compounding pharmacies to prepare popular peptide therapies, overriding the recommendations of the agency's own scientists who opposed the move. Peptide therapies have grown increasingly popular among patients in the United States. The final decision rests with the FDA, which is not bound by the panel's recommendation.